Item Type | Name |
Concept
|
Biliary Tract Neoplasms
|
Concept
|
Breast Neoplasms
|
Concept
|
Bone Neoplasms
|
Concept
|
Bile Duct Neoplasms
|
Concept
|
Cancer Care Facilities
|
Concept
|
Colonic Neoplasms
|
Concept
|
Gastrointestinal Neoplasms
|
Concept
|
Genital Neoplasms, Female
|
Concept
|
Kidney Neoplasms
|
Concept
|
Laryngeal Neoplasms
|
Concept
|
Liver Neoplasms
|
Concept
|
Pancreatic Neoplasms
|
Concept
|
Lung Neoplasms
|
Concept
|
Prostatic Neoplasms
|
Concept
|
Gallbladder Neoplasms
|
Concept
|
Head and Neck Neoplasms
|
Concept
|
Salivary Gland Neoplasms
|
Concept
|
Testicular Neoplasms
|
Concept
|
Thoracic Neoplasms
|
Concept
|
Central Nervous System Neoplasms
|
Concept
|
Neoplasms, Unknown Primary
|
Concept
|
Endometrial Neoplasms
|
Concept
|
Neoplasms, Experimental
|
Concept
|
Cancer Vaccines
|
Concept
|
Peritoneal Neoplasms
|
Concept
|
National Cancer Institute (U.S.)
|
Concept
|
Stomach Neoplasms
|
Concept
|
Skin Neoplasms
|
Concept
|
Colorectal Neoplasms
|
Concept
|
Early Detection of Cancer
|
Concept
|
Hematologic Neoplasms
|
Concept
|
Neoplasms
|
Concept
|
Neoplasms, Glandular and Epithelial
|
Concept
|
Urogenital Neoplasms
|
Academic Article
|
Phase I study of amonafide dosing based on acetylator phenotype.
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
Academic Article
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
Academic Article
|
Adjuvant therapy of colon cancer.
|
Academic Article
|
Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era.
|
Academic Article
|
Adjuvant therapy for colorectal cancer.
|
Academic Article
|
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
|
Academic Article
|
Prospects for fertility after cancer chemotherapy.
|
Academic Article
|
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.
|
Academic Article
|
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
|
Academic Article
|
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
Academic Article
|
Biochemical and clinical pharmacology of 5-fluorouracil.
|
Academic Article
|
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.
|
Academic Article
|
Antifolates: the next generation.
|
Academic Article
|
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
|
Academic Article
|
Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer.
|
Academic Article
|
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
|
Academic Article
|
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
Academic Article
|
Immunotherapy for colorectal cancer.
|
Academic Article
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
Academic Article
|
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
|
Academic Article
|
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
|
Academic Article
|
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
|
Academic Article
|
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
|
Academic Article
|
Construct validity of medicare chemotherapy claims: the case of 5FU.
|
Academic Article
|
End points in cancer clinical trials and the drug approval process.
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
Academic Article
|
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
|
Academic Article
|
Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories.
|
Academic Article
|
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
|
Academic Article
|
Pharmacology and clinical status of capecitabine.
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
Academic Article
|
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
Academic Article
|
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.
|
Academic Article
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
Academic Article
|
Silence is golden: gene hypermethylation and survival in large-cell lymphoma.
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
Academic Article
|
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
|
Academic Article
|
Tumor markers as clinical cancer tests--are we there yet?
|
Academic Article
|
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
|
Academic Article
|
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
|
Academic Article
|
Oral fluoropyrimidine treatment of colorectal cancer.
|
Academic Article
|
Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants.
|
Academic Article
|
Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs.
|
Academic Article
|
Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
|
Academic Article
|
Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B.
|
Academic Article
|
Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
Academic Article
|
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
|
Academic Article
|
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
|
Academic Article
|
Cetuximab in the treatment of colorectal cancer.
|
Academic Article
|
A concise history of the cancer and leukemia group B.
|
Academic Article
|
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
|
Academic Article
|
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
|
Academic Article
|
Is oral tegafur with leucovorin equivalent to intravenous 5-fluorouracil and leucovorin in colorectal cancer?
|
Academic Article
|
Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.
|
Academic Article
|
Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study.
|
Academic Article
|
The role of cooperative groups in cancer clinical trials.
|
Academic Article
|
Drug safety and drug efficacy: two sides of the same coin.
|
Academic Article
|
Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer.
|
Academic Article
|
3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice.
|
Academic Article
|
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
|
Academic Article
|
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
|
Academic Article
|
The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics).
|
Academic Article
|
Introduction: contributions of the cooperative groups.
|
Academic Article
|
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
|
Academic Article
|
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
Academic Article
|
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
|
Academic Article
|
Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program.
|
Academic Article
|
First-line treatment options for patients with metastatic colorectal cancer.
|
Academic Article
|
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
|
Academic Article
|
Are targeted therapies really targeted?
|
Academic Article
|
Personalizing cancer care: American Society of Clinical Oncology presidential address 2009.
|
Academic Article
|
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
|
Academic Article
|
Inhibition of thymidylate synthase by the diastereoisomers of leucovorin.
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
Academic Article
|
Translating the cancer genome into clinically useful tools and strategies.
|
Academic Article
|
Refocusing the war on cancer: the critical role of personalized treatment.
|
Academic Article
|
Personalized medicine in oncology: the future is now.
|
Academic Article
|
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
|
Academic Article
|
Commentary: tackling the challenges of developing targeted therapies for cancer.
|
Academic Article
|
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
Academic Article
|
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.
|
Academic Article
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
Academic Article
|
Male fertility following cancer chemotherapy.
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
Academic Article
|
Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin.
|
Academic Article
|
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.
|
Academic Article
|
Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer.
|
Academic Article
|
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
|
Academic Article
|
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.
|
Academic Article
|
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
|
Academic Article
|
Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience.
|
Academic Article
|
Tumor heterogeneity as the foundation of personalized cancer treatment.
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects.
|
Academic Article
|
WIN Consortium--challenges and advances.
|
Academic Article
|
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
Academic Article
|
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
|
Academic Article
|
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research.
|
Academic Article
|
Personalized cancer medicine - a strategy to counteract an increasing cancer challenge.
|
Academic Article
|
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.
|
Academic Article
|
Clinical trials in the era of personalized oncology.
|
Academic Article
|
Development and use of integral assays in clinical trials.
|
Academic Article
|
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
|
Academic Article
|
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
|
Academic Article
|
How not to treat cancer.
|
Academic Article
|
Accrual to cancer clinical trials in the era of molecular medicine.
|
Academic Article
|
Infertility in patients with testicular cancer: testis, tumor, or treatment?
|
Academic Article
|
Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial.
|
Academic Article
|
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
|
Academic Article
|
Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
|
Academic Article
|
The synthesis and retention of methotrexate polyglutamates in cultured human breast cancer cells.
|
Academic Article
|
Prognostic factors for survival in patients treated in phase I clinical trials.
|
Academic Article
|
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
|
Academic Article
|
Synergistic cytotoxicity and DNA strand break formation by bromodeoxyuridine and bleomycin in human tumor cells.
|
Academic Article
|
Molecular markers to individualize adjuvant therapy for colon cancer.
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
Academic Article
|
Data submission standards and evidence requirements.
|
Academic Article
|
Effects of cancer treatment on the reproductive system.
|
Academic Article
|
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
|
Academic Article
|
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy.
|
Academic Article
|
Toxic effects of cis-dichlorodiammineplatinum(II) in man.
|
Academic Article
|
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
Academic Article
|
Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.
|
Academic Article
|
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
|
Academic Article
|
Update in hematology and oncology: evidence published in 2010.
|
Academic Article
|
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
|
Academic Article
|
High-dose methotrexate: a critical reappraisal.
|
Academic Article
|
Cytarabine-cis-platin interactions in patients with advanced cancer.
|
Academic Article
|
Evaluation of cognition in cancer patients: special focus on the elderly.
|
Academic Article
|
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
|
Academic Article
|
High-pressure liquid chromatography analysis of methotrexate polyglutamates in cultured human breast cancer cells.
|
Academic Article
|
Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells.
|
Academic Article
|
Using patient-initiated study participation in the development of evidence for personalized cancer therapy.
|
Academic Article
|
Gonadal dysfunction in patients receiving chemotherapy for cancer.
|
Academic Article
|
Renal and metabolic toxicities of cancer chemotherapy.
|
Academic Article
|
Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
|
Academic Article
|
Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates.
|
Academic Article
|
Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial.
|
Academic Article
|
Targeted therapy for cancer: asking the right questions.
|
Academic Article
|
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
Academic Article
|
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
|
Academic Article
|
Gonadal and sexual function in male patients with hairy cell leukemia: lack of adverse effects of recombinant alpha 2-interferon treatment.
|
Academic Article
|
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
|
Academic Article
|
A phase I study of intermittent infusion cladribine in patients with solid tumors.
|
Academic Article
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
Academic Article
|
Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
|
Academic Article
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
Academic Article
|
Clinical pharmacology of methotrexate.
|
Academic Article
|
Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer.
|
Academic Article
|
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
|
Academic Article
|
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
|
Academic Article
|
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
|
Academic Article
|
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.
|
Academic Article
|
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
|
Academic Article
|
Ovarian function following radiation and chemotherapy for cancer.
|
Academic Article
|
The next phase of chemoprevention research.
|
Academic Article
|
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
|
Academic Article
|
Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells.
|
Academic Article
|
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.
|
Academic Article
|
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
|
Academic Article
|
Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
|
Academic Article
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
Academic Article
|
Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
|
Academic Article
|
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
|
Academic Article
|
The oral fluoropyrimidines in cancer chemotherapy.
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
Academic Article
|
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
|
Academic Article
|
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
|
Academic Article
|
Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641.
|
Academic Article
|
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
|
Academic Article
|
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
|
Academic Article
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
Academic Article
|
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
Academic Article
|
Modulation of vinblastine resistance with cyclosporine: a phase I study.
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
Academic Article
|
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
|
Academic Article
|
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
|
Academic Article
|
Pharmacodynamics in cancer therapy.
|
Academic Article
|
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
|
Academic Article
|
Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells.
|
Academic Article
|
The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards.
|
Academic Article
|
An accelerated pathway for targeted cancer therapies.
|
Academic Article
|
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
|
Academic Article
|
Role of randomized phase III trials in an era of effective targeted therapies.
|
Academic Article
|
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas.
|
Academic Article
|
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
|
Academic Article
|
Methotrexate polyglutamate synthesis by cultured human breast cancer cells.
|
Academic Article
|
Characteristics of membrane transport of methotrexate by cultured human breast cancer cells.
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
Academic Article
|
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
Academic Article
|
Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations.
|
Academic Article
|
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
|
Academic Article
|
Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24Â hour constant-rate infusion.
|
Academic Article
|
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
|
Academic Article
|
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.
|
Academic Article
|
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
|
Academic Article
|
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
|
Academic Article
|
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012.
|
Academic Article
|
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
|
Academic Article
|
Precision cancer medicine: the future is now, only better.
|
Academic Article
|
Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ.
|
Academic Article
|
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
|
Academic Article
|
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
|
Academic Article
|
Breaking a vicious cycle.
|
Academic Article
|
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.
|
Academic Article
|
Progress against GI cancer during the American Society of Clinical Oncology's first 50 years.
|
Academic Article
|
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
|
Academic Article
|
Drivers of change in cancer care.
|
Academic Article
|
Global Challenges for Cancer Imaging.
|
Academic Article
|
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.
|
Academic Article
|
Response.
|
Academic Article
|
Highlights from the 2013 WIN Symposium: personalised cancer therapy from innovation to implementation.
|
Academic Article
|
Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
|
Academic Article
|
Implementing personalized cancer care.
|
Academic Article
|
ASCO's initiative to define value in cancer care.
|
Academic Article
|
Hans Christian Andersen and the Value of New Cancer Treatments.
|
Academic Article
|
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.
|
Academic Article
|
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.
|
Academic Article
|
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
|
Academic Article
|
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
|
Academic Article
|
Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus.
|
Academic Article
|
Drug approval challenges in the age of personalized cancer treatment.
|
Academic Article
|
Reply to L. Casadaban et al.
|
Academic Article
|
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
|
Academic Article
|
Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
|
Academic Article
|
Reevaluating the accelerated approval process for oncology drugs.
|
Academic Article
|
A New Look at the State of Cancer Care in America.
|
Academic Article
|
Publicly funded clinical trials and the future of cancer care.
|
Academic Article
|
Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology.
|
Academic Article
|
Innovative clinical trials for development of personalized cancer medicine.
|
Academic Article
|
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.
|
Academic Article
|
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
|
Academic Article
|
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
|
Academic Article
|
Moving from evaluation to value in cancer care.
|
Academic Article
|
Integrating biomarkers in colorectal cancer trials in the West and China.
|
Academic Article
|
Recommendations for management of patients with neuroendocrine liver metastases.
|
Academic Article
|
A New IDEA in Adjuvant Chemotherapy for Colon Cancer.
|
Academic Article
|
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
|
Academic Article
|
Wither the cooperative groups?
|
Academic Article
|
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
|
Academic Article
|
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary.
|
Academic Article
|
The evidence framework for precision cancer medicine.
|
Academic Article
|
Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?
|
Academic Article
|
Improving evidence developed from population-level experience with targeted agents.
|
Academic Article
|
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.
|
Academic Article
|
Accelerating anticancer drug development - opportunities and trade-offs.
|
Academic Article
|
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
|
Academic Article
|
Gains Against Cancer, But Enter 'Financial Toxicity'.
|
Academic Article
|
Modernizing Eligibility Criteria for Molecularly Driven Trials.
|
Grant
|
Cancer Center Support Grant
|
Academic Article
|
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
|
Academic Article
|
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
|
Academic Article
|
State of Cancer Care in America: Reflections on an Inaugural Year.
|
Academic Article
|
Implementing Precision Medicine in Community-Based Oncology Programs: Three Models.
|
Academic Article
|
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
|
Academic Article
|
Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise.
|
Academic Article
|
The promise of Immuno-oncology: implications for defining the value of cancer treatment.
|
Academic Article
|
Challenges and approaches to implementing master/basket trials in oncology.
|
Academic Article
|
Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology.
|
Academic Article
|
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
|
Academic Article
|
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
|
Academic Article
|
Talking the Talk About Tumor Genomic Testing.
|
Academic Article
|
Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
|
Academic Article
|
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.
|
Academic Article
|
Reply to M. Hutton-Potts and A.M. Joshua.
|
Academic Article
|
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey.
|
Academic Article
|
Closing the Rural Cancer Care Gap: Three Institutional Approaches.
|
Academic Article
|
The International Collaboration for Cancer Classification and Research.
|
Academic Article
|
Progress in Cancer Research, Prevention, and Care.
|
Academic Article
|
The National Clinical Trials Network and the cooperative groups: The road not taken.
|
Academic Article
|
Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars.
|
Academic Article
|
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
Academic Article
|
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
Academic Article
|
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.
|
Academic Article
|
Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement.
|
Academic Article
|
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.
|
Academic Article
|
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement.
|
Academic Article
|
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
|
Academic Article
|
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
|
Academic Article
|
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
Academic Article
|
'Strategic' development of precision cancer medicine in the United States.
|
Academic Article
|
The Porto European Cancer Research Summit 2021.
|
Academic Article
|
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry.
|
Academic Article
|
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
Academic Article
|
Use of Biosimilar Medications in Oncology.
|
Academic Article
|
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
Academic Article
|
Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States.
|
Academic Article
|
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.
|
Academic Article
|
Beyond the COVID-19 Pandemic: Sustaining and Improving Equitable Cancer Care and Research.
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
|
Academic Article
|
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.
|
Academic Article
|
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
Academic Article
|
Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung.
|
Academic Article
|
Closing the Gap in Cancer Genomic Testing.
|
Academic Article
|
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
|
Concept
|
Prostatic Neoplasms, Castration-Resistant
|
Grant
|
Cancer and Leukemia Group B
|
Grant
|
Cancer and Leukemia Group B Human Specimen Repositories
|
Grant
|
CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
|
Grant
|
CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
|
Grant
|
Cancer and Leukemia Group B CCOP Research Base
|
Grant
|
CELLULAR PHARMACOLOGY OF THE STEREOISOMERS OF LEUCOVORIN
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
Academic Article
|
Health Data Sharing Perspectives of Patients Receiving Care in CancerLinQ-Participating Oncology Practices.
|
Academic Article
|
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.
|
Academic Article
|
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
Academic Article
|
Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank.
|
Academic Article
|
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
Academic Article
|
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
Academic Article
|
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
Academic Article
|
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
|
Academic Article
|
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.
|
Academic Article
|
Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.
|
Academic Article
|
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|